Home » Topics » Disease categories and therapies » Substance use and poisoning

Substance use and poisoning
RSS

Opiant and Titan to develop product for opioid use disorder

Oct. 3, 2017

NIDA grant supports Camino Pharma's development of compounds for substance use disorders

Sep. 29, 2017

Aeolus Pharmaceuticals' AEOL-10150 safe and well-tolerated in phase I study

Sep. 20, 2017

Emergent Biosolutions awarded funding to develop antidote spray for cyanide poisoning

Sep. 20, 2017

FDA accepts Camurus' NDA for CAM-2038 buprenorphine depots

Sep. 19, 2017

FDA grants priority review to Braeburn's NDA for CAM-2038 for opioid use disorder

Sep. 18, 2017

CHMP adopts positive opinion for Zubsolv as treatment of opioid dependence

Sep. 18, 2017

Ophirex licenses sPLA2 inhibitor data from Lilly and Shionogi to support snakebite program

Aug. 29, 2017

Pluristem starts pilot study to test PLX-R18 cell therapy for acute radiation syndrome

Aug. 17, 2017

Soligenix receives additional NIAID funding for the development of heat stable ricin vaccine

Aug. 16, 2017

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...
Gene replacement rescues autism-related phenotypes in mice
BioWorld Science
Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...